🚀 VC round data is live in beta, check it out!
SK Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for SK Bioscience and similar public comparables like Wockhardt, Pfizer India, Ultragenyx, Nektar Therapeutics and more.
SK Bioscience Overview
About SK Bioscience
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and development of vaccines. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further, it has several other vaccines under development and clinical trials, including a recombinant rotavirus vaccine.
Founded
2018
HQ
Employees
1.0K
Website
Sectors
Financials (LTM)
EV
$2B
SK Bioscience Financials
SK Bioscience reported last 12-month revenue of $457M and negative EBITDA of ($114M).
In the same LTM period, SK Bioscience generated ($114M) in EBITDA losses and had net loss of ($43M).
Revenue (LTM)
SK Bioscience P&L
In the most recent fiscal year, SK Bioscience reported revenue of $451M and EBITDA of $10M.
SK Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $457M | XXX | $451M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $52M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA | ($114M) | XXX | $10M | XXX | XXX | XXX |
| EBITDA Margin | (25%) | XXX | 2% | XXX | XXX | XXX |
| EBIT Margin | (28%) | XXX | (19%) | XXX | XXX | XXX |
| Net Profit | ($43M) | XXX | ($39M) | XXX | XXX | XXX |
| Net Margin | (9%) | XXX | (9%) | XXX | XXX | XXX |
| Net Debt | — | — | $245M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SK Bioscience Stock Performance
SK Bioscience has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
SK Bioscience's stock price is $31.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSK Bioscience Valuation Multiples
SK Bioscience trades at 4.8x EV/Revenue multiple, and (19.0x) EV/EBITDA.
EV / Revenue (LTM)
SK Bioscience Financial Valuation Multiples
As of April 19, 2026, SK Bioscience has market cap of $2B and EV of $2B.
Equity research analysts estimate SK Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SK Bioscience has a P/E ratio of (57.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | (19.0x) | XXX | 219.4x | XXX | XXX | XXX |
| EV/EBIT | (17.3x) | XXX | (25.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 42.1x | XXX | XXX | XXX |
| P/E | (57.9x) | XXX | (63.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SK Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SK Bioscience Margins & Growth Rates
SK Bioscience's revenue in the last 12 month grew by 5%.
SK Bioscience's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
SK Bioscience's rule of 40 is (8%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SK Bioscience's rule of X is 1% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SK Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | (25%) | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | (41%) | XXX | (801%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (8%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SK Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Ultragenyx | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Bioscience M&A Activity
SK Bioscience acquired XXX companies to date.
Last acquisition by SK Bioscience was on XXXXXXXX, XXXXX. SK Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SK Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSK Bioscience Investment Activity
SK Bioscience invested in XXX companies to date.
SK Bioscience made its latest investment on XXXXXXXX, XXXXX. SK Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SK Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SK Bioscience
| When was SK Bioscience founded? | SK Bioscience was founded in 2018. |
| Where is SK Bioscience headquartered? | SK Bioscience is headquartered in South Korea. |
| How many employees does SK Bioscience have? | As of today, SK Bioscience has over 1K employees. |
| Is SK Bioscience publicly listed? | Yes, SK Bioscience is a public company listed on Korea Exchange. |
| What is the stock symbol of SK Bioscience? | SK Bioscience trades under 302440 ticker. |
| When did SK Bioscience go public? | SK Bioscience went public in 2021. |
| Who are competitors of SK Bioscience? | SK Bioscience main competitors are Wockhardt, Pfizer India, Ultragenyx, Nektar Therapeutics. |
| What is the current market cap of SK Bioscience? | SK Bioscience's current market cap is $2B. |
| What is the current revenue of SK Bioscience? | SK Bioscience's last 12 months revenue is $457M. |
| What is the current revenue growth of SK Bioscience? | SK Bioscience revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of SK Bioscience? | Current revenue multiple of SK Bioscience is 4.8x. |
| Is SK Bioscience profitable? | No, SK Bioscience is not profitable. |
| What is the current EBITDA of SK Bioscience? | SK Bioscience has negative EBITDA and is not profitable. |
| What is SK Bioscience's EBITDA margin? | SK Bioscience's last 12 months EBITDA margin is (25%). |
| What is the current EV/EBITDA multiple of SK Bioscience? | Current EBITDA multiple of SK Bioscience is (19.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.